- Home
- INTS vs SBFM Comparison
INTS vs SBFM Comparison
Compare INTS & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- SBFM
- Stock Information
- Founded
- INTS 2012
- SBFM 2006
- Country
- INTS United States
- SBFM United States
- Employees
- INTS N/A
- SBFM N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- INTS Health Care
- SBFM Health Care
- Exchange
- INTS Nasdaq
- SBFM Nasdaq
- Market Cap
- INTS 8.0M
- SBFM 6.6M
- IPO Year
- INTS 2023
- SBFM N/A
- Fundamental
- Price
- INTS $0.31
- SBFM $1.57
- Analyst Decision
- INTS Strong Buy
- SBFM Strong Buy
- Analyst Count
- INTS 3
- SBFM 1
- Target Price
- INTS $8.50
- SBFM $15.00
- AVG Volume (30 Days)
- INTS 3.1M
- SBFM 190.5K
- Earning Date
- INTS 08-07-2025
- SBFM 08-15-2025
- Dividend Yield
- INTS N/A
- SBFM N/A
- EPS Growth
- INTS N/A
- SBFM N/A
- EPS
- INTS N/A
- SBFM N/A
- Revenue
- INTS N/A
- SBFM $36,234,578.00
- Revenue This Year
- INTS N/A
- SBFM $192.48
- Revenue Next Year
- INTS N/A
- SBFM N/A
- P/E Ratio
- INTS N/A
- SBFM N/A
- Revenue Growth
- INTS N/A
- SBFM 35.51
- 52 Week Low
- INTS $0.26
- SBFM $1.17
- 52 Week High
- INTS $5.10
- SBFM $7.60
- Technical
- Relative Strength Index (RSI)
- INTS 40.08
- SBFM 50.10
- Support Level
- INTS $0.26
- SBFM $1.43
- Resistance Level
- INTS $0.32
- SBFM $1.75
- Average True Range (ATR)
- INTS 0.04
- SBFM 0.11
- MACD
- INTS 0.02
- SBFM 0.00
- Stochastic Oscillator
- INTS 49.20
- SBFM 30.56
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.